In the life sciences sector, capital allocation often tells a clearer story than pure drug discovery. While pharmaceutical giants spend billions to develop and commercialize late-stage therapies, specialized royalty acquirers deploy targeted capital to harvest the long-term cash flows generated by those same drugs.

A prime example unfolded when Royalty Pharma plc (NASDAQ:RPRX) acquired a portion of Neurimmune’s royalty interest in AstraZeneca PLC (NYSE:AZN) candidate cliramitug. Royalty Pharma agreed to pay Neurimmune up to $425 million, starting with $125 million upfront, in exchange for a 3% to 4% royalty on global net sales. In the first quarter of 2027, Royalty Pharma will pay another $125 million in cash, with the remaining $175 million tied to clinical and regulatory milestones.

Cliramitug is currently in the Phase 3 DepleTTR-CM trial, with data readouts expected in 2028. It represents a unique therapeutic approach to transthyretin amyloidosis with cardiomyopathy (ATTR-CM), a fatal condition caused by misfolded protein accumulation in the heart. Current approved treatments only slow progression by preventing new amyloid build-up. Cliramitug, by contrast, is a TTR-fibril-depleting antibody designed to actually clear existing deposits. This distinction positions the asset as a high-reward addition to AstraZeneca’s rare disease footprint and a strong cash-flow generator for Royalty Pharma if Phase 3 succeeds.

Royalty Pharma plc (NASDAQ:RPRX) vs. AstraZeneca PLC (NYSE:AZN): How Are Both Doing?

When comparing performance, we must note an accounting mismatch: AstraZeneca PLC recently reported its Q2 and H1 2026 results, whereas Royalty Pharma plc’s most recent report covers Q1 2026 (its Q2 earnings have not been released yet). Comparing a Q1 period directly against a Q2 period isn’t apple-to-apples, but reviewing their financial trajectories shows both companies executing well in their respective models.

AstraZeneca (Q2 / H1 2026 Financials):

AstraZeneca PLC continues to run at scale. In H1 2026, total revenue rose 6%, propelled by double-digit expansion across Oncology and Rare Disease. This growth helped offset headwinds from loss of exclusivity on Farxiga in the U.S. and price pressures in China. Core operating profit and Core EPS both advanced by 11%, demonstrating solid operating leverage. The company’s management reconfirmed full-year 2026 guidance and increased the interim dividend by 3 cents to $1.06 per share. CEO Pascal Soriot pointed out that six Phase 3 readouts hit positively in the first half. However, the company did hit a snag with its CARDIO-TTRansform trial outcome, underscoring the execution risk inherent in traditional drug development.

Royalty Pharma (Q1 2026 Financials & Q2 Outlook):

Royalty Pharma plc’s top-line model relies on Portfolio Receipts, the sum of its royalty streams and milestone payments. In Q1 2026, Portfolio Receipts rose 10% year-over-year to $925 million, while Royalty Receipts climbed 13% to $887 million. Key performers included Tremfya, Voranigo, and Evrysdi, which easily offset U.S. generic pressure on Promacta. Net cash from operations jumped 20% to $718 million, and Adjusted EBITDA rose 21% to $889 million. On the back of this strength, Royalty Pharma raised its full-year 2026 Portfolio Receipts guidance to between $3.325 billion and $3.450 billion.

Which Company Is Doing Better?

Because Royalty Pharma plc hasn’t published its Q2 numbers yet, its reported figures lag AstraZeneca by a quarter. However, Royalty Pharma looks poised to deliver an even stronger Q2. In Q1 2026 alone, RPRX deployed $528 million into new deals and announced up to $1.25 billion in total transaction value, including major R&D co-funding agreements with Johnson & Johnson and Teva.

As the commercial drugs in its portfolio (like Tremfya and Evrysdi) keep ramping up, Royalty Pharma’s high-margin business model allows cash flow to flow down to the bottom line without the direct clinical trial costs, commercial sales-force overhead, or drug development failures that burden traditional pharma. Therefore, while AstraZeneca PLC carries higher absolute revenue scale, Royalty Pharma is generating cleaner cash flow growth and broader diversification across multiple partners.

The Bull and Bear Cases

Royalty Pharma plc (NASDAQ:RPRX)

Royalty Pharma’s bull case is supported by its low-overhead, high-margin business model. By acquiring royalty interests across more than 35 approved therapies and 19 development-stage candidates, the company gains exposure to biotech innovation while avoiding the full financial burden and binary risks associated with funding clinical trials directly. Its expansion into R&D co-funding partnerships with major pharmaceutical companies also creates a steady pipeline of future royalty opportunities.

The bear case centers on Royalty Pharma’s dependence on the commercial performance of its partners. Factors such as patent expirations, earlier-than-expected generic competition, including risks surrounding products like Promacta, or clinical setbacks within partnered pipelines could negatively impact the company’s long-term royalty cash flows.

AstraZeneca PLC (NYSE:AZN)

AstraZeneca’s bull case is driven by its strong commercial position in oncology and rare diseases. With more than 20 major Phase 3 readouts expected over the next 18 months, the company has multiple opportunities to expand its portfolio and quickly commercialize successful pipeline assets following regulatory approvals.

The bear case involves the significant investment required to maintain its growth trajectory. High R&D spending exposes AstraZeneca to potential trial failures, such as the setback from CARDIO-TTRansform, while upcoming patent expirations, including Farxiga, and evolving government pricing policies increase pressure on the company to consistently deliver new pipeline successes.

Insider Monkey’s Hedge Fund Data

Hedge fund ownership for Royalty Pharma plc increased to 42 funds in Q1 2026, up from 39 funds in Q4 2025, indicating a gradual improvement in institutional interest. Among notable holders, Sciencast Management, led by Qing Li, held 30,073 shares valued at approximately $1.69 million after reducing its position by 32% during the quarter. The stake represented 0.35% of the firm’s portfolio.

Similarly, AstraZeneca also saw rising institutional participation, with hedge fund holders increasing to 56 in Q1 2026 from 52 in Q4 2025. Gotham Asset Management, led by Joel Greenblatt, held 2,868 shares valued at approximately $566,000 after increasing its position by 38%. Meanwhile, NWI Management, led by Hari Hariharan, maintained a stable position of 25,000 shares valued at approximately $4.93 million, representing 0.28% of its portfolio.

Conclusion

The cliramitug transaction highlights how two distinct business models interact in healthcare. AstraZeneca takes on the clinical and regulatory heavy lifting required to bring a novel amyloid-depleting therapy through Phase 3 trials. Meanwhile, Royalty Pharma uses its balance sheet to acquire a low-risk, capped-upside royalty stream that boosts its growing cash flow portfolio.

While AstraZeneca offers massive global commercial scale, Royalty Pharma’s business model, free from heavy internal R&D overhead and supported by recent guidance raises, makes it an exceptionally disciplined compounder for investors seeking healthcare exposure with less trial-failure volatility.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.